Metabolic Consequences of Cross-sex Hormonal Treatment

Central Hospital, Nancy, France98 enrolled

Overview

Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-affirming hormone therapy and in controls

Study Type

OBSERVATIONAL

Enrollment

Conditions

Gender Dysphoria

Interventions

Gender-affirming hormone therapyOTHER

Gender-affirming hormone therapy according to the recommendations of the Endocrine Society

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria (retrospective analysis of available data as a part of the regular care of subjects with gender dysphoria. All measurements were made at the time of the routine follow-up visits) * age \>= 16 years (Tanner stage IV) and \<= 50 years at the initiation of gender-affirming hormone therapy; * BMI \< 28 kg/m2 at the initiation of cross-sex hormonal treatment. Exclusion Criteria: * hormonal contraception * previous gender-affirming hormonal treatment * previous gender-affirming surgery * recognized syndrome or chromosomal defect, known metabolic or inflammatory disease, skeletal dysplasia, or chronic corticosteroid treatment.

Locations (1)

CHRU Nancy

Nancy, France

Outcomes

Primary Outcomes

Retrospective analysis of existing data collected as a part of the regular follow-up

Retrospective analysis of existing data :Anthropometric parameters, including systolic blood pressure (SBP), diastolic blood pressure (DBP), body weight and height at fasting state, were measured in all subjects at the occasion of the routine follow-up visits. Body mass index (BMI) was calculated as body weight in kilograms divided by the height in meter squared (kg/m2). Body composition parameters, including lean mass (LM), total body fat (BF), android and gynoid fat, and bone mineral content, were determined using dual-energy X-Ray absorbtiometry (DXA) (GE-Healthcare Lunar iDXA system), biochemical and routine hormonal analysis

Time frame: Retrospective analysis of data between 2004 and 2019

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.